mitomycin and Carcinoma, Epidermoid studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Research Excerpts

Excerpt	Relevance	Reference
"Based on the observation of topoisomerase-1, upregulation by mitomycin C (MMC), and the phase I antitumor activity of sequential MMC/irinotecan in esophageal cancer, we conducted a phase II evaluation of two schedules of this combination in previously untreated stage III/IV esophageal/gastroesophageal junction adenocarcinomas."	9.14	Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. ( Abbas, A; Bekaii-Saab, T; Burak, W; Lustberg, MB; Lustberg, ME; McCracken-Bussa, B; Otterson, G; Villalona-Calero, MA; Young, D, 2010)
"The purpose of this study is to evaluate the efficacy of a dose-escalated, accelerated, and hyperfractionated radiotherapy schedule with a concomitant single dose of mitomycin C in the treatment of patients with advanced laryngeal or hypopharyngeal cancer."	9.11	Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer. ( Aaltonen, LM; Atula, T; Kajanti, M; Kouri, M; Mäkitie, A; Mäntylä, M; Saarilahti, K, 2004)
"A prospective randomized study to compare the effectiveness of pleurodesis by two new sclerosing agents: OK-432 and mitomycin C were conducted in 53 patients with malignant pleural effusion caused by lung cancer."	9.07	Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. ( Chang, DB; Kuo, SH; Lee, LN; Luh, KT; Yang, PC; Yu, CJ, 1992)
" A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin."	7.81	Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015)
"To assess the role of mitomycin C (MMC) in the management of pharyngoesophageal stricture after total laryngopharyngectomy and free flap reconstruction."	7.72	Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction. ( Annino, DJ; Goguen, LA, 2003)
" In this study we aimed to evaluate the effectivity of postsurgical chemotherapy of conjunctival squamous cell carcinoma in situ (CIN) with mitomycin C eyedrops."	7.71	[Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control]. ( Böcking, A; Cartsburg, O; Kersten, A; Nadjari, B; Pomjanski, N; Sundmacher, R, 2001)
"KW 2083, which is a new mitomycin C derivative currently under clinical investigation, was tested for its antitumor effect on the growth of human carcinoma of the lung by using an in vitro clonogenic assay system."	7.67	Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay. ( Hoshi, A; Kanzawa, F; Matsushima, Y; Miyazawa, N; Saijo, N; Shimizu, E, 1985)
"The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer."	6.80	Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015)
"To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with MMC and fluorouracil (5-FU)."	6.74	Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). ( Bosset, JF; Collette, L; Haustermans, K; Koswig, S; Maingon, P; Matzinger, O; Mineur, L; Mueller, RP; Radosevic-Jelic, L; Roelofsen, F; Van Der Steen-Banasik, EM; Van Houtte, P, 2009)
"The patient is staged as having T2N3 squamous cell carcinoma of the anal canal (Table 1)."	5.38	Mitomycin in anal cancer: still the standard of care. ( Chin, JY; Hong, TS; Ryan, DP, 2012)
"Mitomycin C (MMC) was applied to the area at a dose of 0."	5.37	Periocular allergic contact dermatitis following topical Mitomycin C eye drop application. ( Cavdar, M; Cumurcu, T; Sener, S, 2011)
"We observed euploid DNA-polyploidy and cytomorphological changes in all patients (19/19)."	5.31	Topical mitomycin C and radiation induce conjunctival DNA-polyploidy. ( Böcking, A; Cartsburg, O; Hillenkamp, J; Kallen, C; Pomjanski, N; Sundmacher, R, 2001)
" There was a significant correlation between the area under the time versus concentration curve (AUC) of MMC and the age of patients (r = 0."	5.28	Pharmacokinetic study of mitomycin C with emphasis on the influence of aging. ( Karato, A; Miya, T; Saijo, N; Sasaki, Y, 1992)
"Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2."	5.28	Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991)
"Patients with SCC of anal cancer T2-4N0M0 or T (any) N1-3M0, with good performance status and normal blood and renal function, were treated with capecitabine 825 mg/m(2) bid during radiotherapy associated with a single dose of mitomycin 15 mg/m(2) on day 1."	5.22	Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. ( Alex, AK; Bariani, G; Braghirolli, MI; Hoff, PM; Moniz, CM; Nahas, C; Oliveira, SC; Riechelmann, R, 2016)
"To evaluate toxicity, local control, and survival of anal cancer patients treated with helical tomotherapy (HT) and concurrent 5-fluorouracil and mitomycin-C (5FU/MMC)."	5.20	Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer. ( Doll, C; Field, C; Ghosh, S; Joseph, K; Mulder, K; Nijjar, T; Nijjar, Y; Schiller, D; Severin, D; Syme, A; Tankel, K; Usmani, N; Warkentin, H; Wong, C, 2015)
"Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer."	5.17	Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013)
"The results of our trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50."	5.17	Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. ( Begum, R; Cunningham, D; Essapen, S; Falk, S; Glynne-Jones, R; Gollins, S; James, RD; Kadalayil, L; Ledermann, J; Leslie, M; Maughan, T; McDonald, A; Meadows, HM; Myint, AS; Saunders, MP; Sebag-Montefiore, D; Wilson, C, 2013)
"The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin."	5.17	Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. ( Ajani, JA; Benson, AB; Gunderson, LL; Haddock, MG; Mayer, RJ; Moughan, J; Pedersen, JE; Rich, TA; Thomas, CR; Willett, CG; Winter, KA, 2013)
"A multi-institutional phase 2 trial assessed the utility of dose-painted intensity modulated radiation therapy (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from RTOG 9811."	5.17	RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. ( Esthappan, J; Goodyear, MD; Haddock, MG; Kachnic, LA; Myerson, RJ; Parikh, PJ; Rotman, M; Safran, H; Willett, CG; Willins, J; Winter, K, 2013)
"The United Kingdom Coordinating Committee on Cancer Research anal cancer trial demonstrated the benefit of combined modality treatment (CMT) using radiotherapy (RT), infusional 5-fluorouracil, and mitomycin C over RT alone."	5.15	"Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). ( Adams, R; Glynne-Jones, R; Gollins, S; James, R; Jitlal, M; McDonald, A; Meadows, HM; Northover, JM; Sebag-Montefiore, D, 2011)
" Twenty-one patients with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian cancer, 1 pseudomyxoma peritonei, 1 malignant mesothelioma) were treated with CRS + HIPEC with hydroxycamptothecin 20 mg and mitomycin C 30 mg in 12,000 mL of normal saline at 43 +/- ."	5.14	Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. ( al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW, 2009)
"Based on the observation of topoisomerase-1, upregulation by mitomycin C (MMC), and the phase I antitumor activity of sequential MMC/irinotecan in esophageal cancer, we conducted a phase II evaluation of two schedules of this combination in previously untreated stage III/IV esophageal/gastroesophageal junction adenocarcinomas."	5.14	Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. ( Abbas, A; Bekaii-Saab, T; Burak, W; Lustberg, MB; Lustberg, ME; McCracken-Bussa, B; Otterson, G; Villalona-Calero, MA; Young, D, 2010)
"Patients with previously untreated anal canal cancers with T3 or T4 tumors and/or extensive nodal involvement (bulky N2 or N3) received two 28-day cycles of induction treatment with infusional FU plus cisplatin followed by two 28-day cycles of FU plus mitomycin C with concurrent split-course radiation."	5.13	Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). ( Budinger, S; Colacchio, TA; Day, JM; Ellerton, J; Goldberg, RM; Hopkins, J; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Shank, B; Tepper, J; Valone, F, 2008)
"The purpose of this study is to evaluate the efficacy of a dose-escalated, accelerated, and hyperfractionated radiotherapy schedule with a concomitant single dose of mitomycin C in the treatment of patients with advanced laryngeal or hypopharyngeal cancer."	5.11	Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer. ( Aaltonen, LM; Atula, T; Kajanti, M; Kouri, M; Mäkitie, A; Mäntylä, M; Saarilahti, K, 2004)
"A prospective randomized study to compare the effectiveness of pleurodesis by two new sclerosing agents: OK-432 and mitomycin C were conducted in 53 patients with malignant pleural effusion caused by lung cancer."	5.07	Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. ( Chang, DB; Kuo, SH; Lee, LN; Luh, KT; Yang, PC; Yu, CJ, 1992)
" Twenty-four patients with malignant pericardial effusion were treated by intrapericardial instillation of anti-cancer drugs, such as Carbazilquinone, Mitomycin-C or ACNU, with pericardial drainage."	5.05	[Local application of anti-cancer drugs for the treatment of malignant pleural and pericardial effusion]. ( Fukuoka, M; Matsui, K; Negoro, S; Ryu, S; Sakaguchi, K; Sakai, N; Takada, M; Tamai, S, 1984)
" Twenty-five cases of advanced cervical cancer (15 cases of stage II with high risks, 10 of stage III, referred to as the 254-S group) treated by NAC using nedaplatin, mitomycin C and peplomycin were compared with 30 cases (22 cases of stage II with high risks, 8 of stage III, referred to as the CDDP group) treated using cisplatin and mitomycin C which is the conventional regimen, in terms of measurable response, pathological response, rate of lymph node metastasis, cumulative survival rate, side effects and relapse style."	4.82	[Neoadjuvant intraarterial chemotherapy with nedaplatin, peplomycin and mitomycin C for advanced cervical cancer]. ( Aso, T; Ichimura, M; Ohara, M; Otsuka, I; Shimabukuro, K; Somekawa, Y; Terauchi, T; Tsugata, M; Umeki, H; Wakana, K; Yamaguchi, Y, 2003)
"Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy."	4.40	Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023)
"Between 2000 and 2015, a total of 112 consecutive patients with UICC stage I-IV anal cancer received chemoradiotherapy with 5‑fluororuracil and mitomycin C (CRT)."	3.91	Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. ( Fietkau, R; Grützmann, R; Matzel, KE; Ott, OJ; Raptis, D; Schmidt, M; Schneider, I; Semrau, S; Strnad, V; Uter, W, 2019)
"Definitive chemoradiation with concurrent 5-fluorouracil (5-FU)/mitomycin C (MMC) is an effective treatment for localized anal cancer, but it is associated with significant acute long-term treatment-related toxicity."	3.91	Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. ( Adams, J; Allen, JN; Baglini, C; Ben-Josef, E; Blaszkowsky, LS; Clark, JW; DeLaney, TF; Drapek, LC; Hong, TS; Jiang, W; Metz, JM; Murphy, JE; Parikh, AR; Plastaras, JP; Ryan, DP; Wo, JY; Yeap, BY, 2019)
"During a regular MR control, the patient developed anaphylactic reaction to Gadolinium, and after that a rectosigmoid ischemia with total necrosis of the posterior rectal wall was diagnosed and surgically treated with Hartmann procedure."	3.91	Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication. ( Calvisi, G; Carlei, F; Di Sibio, A; Di Staso, M; Giuliani, A; Lombardi, L; Marchese, M; Romano, L; Romanzi, F; Schietroma, M, 2019)
" We investigated the prognostic role of baseline hemoglobin (Hb) in a cohort of anal cancer patients submitted to CT-RT with 5-fluorouracil and mitomycin C."	3.88	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. ( Andrikou, K; Arcadipane, F; Casadei Gardini, A; Casadei, C; Cascinu, S; Cassoni, P; Fornaro, L; Franco, P; Iorio, GC; Martini, S; Mistrangelo, M; Montagnani, F; Ricardi, U; Scartozzi, M, 2018)
"NRG Oncology RTOG 0529 assessed the feasibility of dose-painted intensity modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer."	3.85	Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. ( Abitbol, A; Chang, A; Chen, Y; Crane, CH; Doncals, DE; Fisher, B; Johnson, D; Kachnic, L; Michalski, J; Moughan, J; Myerson, R; Narayan, S; Olsen, JR; Schefter, TE, 2017)
"Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C."	3.85	Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. ( Aggarwal, S; Bazan, JG; Chang, DT; Golden, DW; Kopec, M; Lee, AY; Liauw, SL; Pelizzari, CA, 2017)
" A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin."	3.81	Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015)
"Concurrent chemoradiotherapy with 5-fluorouracil (5-FU) and mitomycin-C (MMC) is standard treatment for anal cancer."	3.81	Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C. ( Aleshin, A; Goldman, K; Lien, WW; Rao, AR; White, EC, 2015)
"Between 1976 and 2008, 116 patients with T2 node-negative anal cancer were treated curatively with RT alone (n=48) or by combined chemoradiation therapy (CRT) (n=68) incorporating mitomycin C and 5-fluorouracil."	3.79	Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. ( Allal, AS; Betz, M; Bieri, S; Ris, F; Roche, B; Roth, AD; Zilli, T, 2013)
"Twelve patients with progressive dysphagia and video-fluoroscopic evidence of upper digestive tract stricture after head and neck cancer treatment were dilated by Maloney or Savory dilators followed by the application of mitomycin C (0."	3.74	Role of mitomycin in upper digestive tract stricture. ( Brodsky, MB; Day, TA; Gillespie, MB; Martin-Harris, B; Sharma, AK, 2007)
"To assess the role of mitomycin C (MMC) in the management of pharyngoesophageal stricture after total laryngopharyngectomy and free flap reconstruction."	3.72	Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction. ( Annino, DJ; Goguen, LA, 2003)
" In this study we aimed to evaluate the effectivity of postsurgical chemotherapy of conjunctival squamous cell carcinoma in situ (CIN) with mitomycin C eyedrops."	3.71	[Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control]. ( Böcking, A; Cartsburg, O; Kersten, A; Nadjari, B; Pomjanski, N; Sundmacher, R, 2001)
"Forty-two consecutive patients with anal canal cancer were treated with 15 fractions of 30-Gy photon beam radiation therapy administered anteroposterior-posteroanterior in conjunction with chemotherapy with 5-fluorouracil and mitomycin C."	3.69	Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy. ( Anderson, PJ; Frost, DB; Kagan, AR; Latino, F; Peddada, AV; Rao, AR; Shah, KH; Smith, DE, 1994)
"The multidrug resistance gene product P-glycoprotein (P-GP) was assessed immunohistochemically (by antibody JSB-1) in biopsy specimens from 27 oesophageal squamous carcinomas and 10 adenocarcinomas before treatment with mitomycin, ifosfamide and cisplatin (MIC)."	3.69	Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer. ( Darnton, SJ; Ferry, DR; Jenner, K; Matthews, HR; Steyn, RS, 1995)
"Of 13 patients with adenocarcinoma treated with 5-fluorouracil, adriamycin, and mitomycin (FAM), nine showed minor histological changes compared with 14 control cases."	3.68	Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. ( Allen, SM; Darnton, SJ; Edwards, CW; Matthews, HR, 1993)
"A 63-year-old male had undergone combination chemotherapy including adriamycin, cisplatin, mitomycin C, 5-fluorouracil and vindesine for six months for double cancer of esophagus and stomach."	3.68	[Chemotherapy-associated hemolytic uremic syndrome--a case report]. ( Kanamaru, R; Kikuchi, H, 1992)
" The nausea and vomiting were reasonably well controlled with methylprednisolone and metoclopramide."	3.67	[Clinical study of chemotherapy (PPM therapy) with cisplatin, peplomycin and mitomycin C in squamous cell lung cancer]. ( Arai, S; Honda, Y; Ito, T; Kato, M; Kawata, Y; Kori, Y; Koyama, M, 1986)
" Treatment regimens usually employed cis-diammine-dichloroplatinum (CDDP) plus peplomycin for squamous cell carcinoma, and CDDP plus vindesine for adenocarcinoma."	3.67	[Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion]. ( Inoue, F; Mimura, H; Miyake, M; Mori, T; Orita, K; Takeda, I; Tanaka, N, 1988)
"KW 2083, which is a new mitomycin C derivative currently under clinical investigation, was tested for its antitumor effect on the growth of human carcinoma of the lung by using an in vitro clonogenic assay system."	3.67	Evaluation of a new drug 7-N-(p-hydroxyphenyl)-mitomycin C [KW 2083] against carcinoma of the lung by the human tumor clonogenic assay. ( Hoshi, A; Kanzawa, F; Matsushima, Y; Miyazawa, N; Saijo, N; Shimizu, E, 1985)
"Neoadjuvant therapy combining 5-fluorouracil, mitomycin C, and moderate-dose radiotherapy was given preoperatively to 29 patients with adenocarcinoma of the rectum, 3 patients with squamous cell cancer, and 1 patient with basaloid carcinoma of the anus."	3.67	Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. ( Muff, NS; Shetabi, H; Smith, DE, 1986)
"We report 5 cases of invasive squamous cell bladder cancer treated with preoperative mitomycin C and 5-fluorouracil in combination with preoperative external beam radiation therapy (the Nigro regimen), and the subsequent apparent cure of 3 of the 5 patients."	3.67	A new treatment for invasive squamous cell bladder cancer: the Nigro regimen: preoperative chemotherapy and radiation therapy. ( Gee, WF; Medina, WD; Mendiondo, OA; Patterson, JM; Ray, EH, 1988)
" Time of resolution and frequency of adverse effects were analyzed to determine the pharmacological efficacy and safety of both medications."	3.30	Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy. ( Alvarado-Castillo, B; Garcia-Benavides, L; Gonzalez-Castillo, C; Navarro-Partida, J; Rosales-Gradilla, ME; Santa Cruz-Pavlovich, FJ; Vidal-Paredes, IA, 2023)
"Anal squamous cell carcinoma (ASqCC) is a rare malignancy, traditionally treated with combined chemoradiation, with a continuous infusion of 5-fluorouracil (5-FU) and mitomycin C (MMC)."	3.01	Comparison of intravenous 5-Fluorouracil with Oral Capecitabine in the Treatment of Anal Squamous Cell Carcinoma Using Modern Radiation Techniques. ( Ben David, MA; Grinberg, V; Hod, K; Kalmus, Y; Levin, D; Lipski, Y; Pfeffer, RM; Schlosser, S; Zalmanov, S, 2023)
" A pharmacokinetic study was performed in 18 patients."	2.84	Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques. ( Clementi, M; Fiorentini, G; Guadagni, S; Mambrini, A; Masedu, F; Palumbo, P, 2017)
"Anal cancer is considered a rare tumor, accounting for 6 % of digestive cancers and about 2000 new cases per year in France."	2.82	[Anal cancer: Focus on current treatment and future perspective]. ( Combet-Curt, V; Delhiat, AC; Vendrely, V, 2022)
"Cervical squamous carcinoma patients who were pathologically diagnosed with stage Ib-IIb from April 2012 to May 2013 in the general hospital of Chinese People's Libration Amy were enrolled."	2.80	A clinical Comparison of Lobaplatin or Cisplatin with Mitomycine and Vincristine in Treating Patients with Cervical Squamous Carcinoma. ( Chen, L; Li, WP; Liu, H; Yao, YQ; Zhao, EF, 2015)
"The treatment for squamous cell carcinoma of the anus changed dramatically during the study period."	2.80	The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus. ( Aravani, A; Downing, A; Finan, PJ; Lawton, S; Morris, EJ; Sebag-Montefiore, D; Thomas, JD, 2015)
"The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer."	2.80	Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015)
"Chemoradiotherapy (CRT) for squamous cell carcinoma of the anus (SCCA) may cause significant toxicity, and concerns exist about its tolerability in the elderly."	2.79	Impact of advancing age on treatment and outcomes in anal cancer. ( Chander, S; Chu, J; Foo, M; Heriot, A; Lee, MT; Leong, T; Link, E; Michael, M; Ngan, SY; Tomaszewski, JM; Tran, PK, 2014)
"Patients with stage IB2, IIA2, or IIB squamous cell carcinoma of the uterine cervix were randomly assigned to receive either BOMP (bleomycin 7 mg days 1-5, vincristine 0."	2.78	Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). ( Hiura, M; Kamura, T; Kasamatsu, T; Katsumata, N; Kobayashi, H; Kodama, S; Kuzuya, K; Mizunoe, T; Nakanishi, T; Saito, T; Shibata, T; Yaegashi, N; Yasugi, T; Yokota, H; Yoshikawa, H, 2013)
" Maintenance chemotherapy started 4-8 weeks later, three courses repeated every 21 days, using 5-FU/CDDP doses above, with MMC reduced to 7 mg/m(2) and administered with the first and third cycles."	2.77	Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. ( Cunningham, D; Davidson, N; Glynne-Jones, R; Grieve, R; Hurman, DC; Levine, E; Meadows, HM; Plowman, PN; Sebag-Montefiore, D, 2012)
"Ocular lesions in horses, confirmed as squamous cell carcinoma, were treated topically with mitomycin C."	2.75	Mitomycin C, with or without surgery, for the treatment of ocular squamous cell carcinoma in horses. ( Knottenbelt, D; Malalana, F; McKane, S, 2010)
"To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with MMC and fluorouracil (5-FU)."	2.74	Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). ( Bosset, JF; Collette, L; Haustermans, K; Koswig, S; Maingon, P; Matzinger, O; Mineur, L; Mueller, RP; Radosevic-Jelic, L; Roelofsen, F; Van Der Steen-Banasik, EM; Van Houtte, P, 2009)
"Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone."	2.73	Combined modality chemoradiation in elderly oesophageal cancer patients. ( Anderson, SE; Bains, M; Hummer, A; Ilson, DH; Kelsen, D; Minsky, BD, 2007)
"Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient."	2.73	Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008)
"Patients with advanced head and neck cancer were treated with primary curative radiotherapy (66 Gy in 33 fractions with five fractions per week) +/-a single injection (15 mg/m(2)) of MMC at the end of the first week of radiotherapy."	2.71	Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. ( Abeyakoon, S; Dinshaw, KA; Grau, C; Hadjieva, T; Jabeen, K; Overgaard, J; Prakash Agarwal, J; Rab Khan, A; Tatsuzaki, H; Turkan, S; Wahid, I, 2003)
" Haematological toxicity and dosage reductions were higher with SuperMIP, which was nevertheless associated with a significantly increased absolute dose intensity."	2.71	A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. ( Berghmans, T; Corhay, JL; Efremidis, A; Giner, V; Koumakis, G; Lafitte, JJ; Lecomte, J; Lothaire, P; Mommen, P; Ninane, V; Paesmans, M; Richez, M; Sculier, JP; Thiriaux, J; Van Houtte, P; Wackenier, P, 2004)
"CPT-11 combined with MMC can be effective against advanced or recurrent SCC of the uterine cervix."	2.71	Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. ( Fujii, T; Fushiki, H; Hasegawa, K; Izumi, R; Nishida, M; Nishimura, R; Takizawa, K; Tanaka, T; Umesaki, N; Yamamoto, K, 2004)
"The purpose of this pilot study was to evaluate the feasibility and toxicity of concurrent chemotherapy with vinorelbine and mitomycin C in combination with accelerated radiotherapy (RT) in patients with locally advanced cancer of the head and neck."	2.71	A new concurrent chemotherapy with vinorelbine and mitomycin C in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. ( Dellian, M; Dühmke, E; Pachmann, S; Schalhorn, A; Schymura, B; Wilkowski, R, 2005)
"Patients with FIGO Stage IIIb cervical cancer show cancer propagation to pelvic side walls from the uterus, and the tumors cannot be completely removed by radical hysterectomy."	2.71	Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study. ( Kokawa, K; Tanaka, T; Umesaki, N, 2005)
"Mitomycin-C/cisplatin were used to treat 33 evaluable patients aged 29-67 years (median: 50 years)."	2.70	Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. ( Anastasopoulou, A; Einhorn, N; Lacave, AJ; Mangioni, C; Neijt, JP; Pecorelli, S; Rotmensz, N; van der Burg, ME; van Oosterom, AT; Veenhof, CH; Vermorken, JB; Wagenaar, HC; Zola, P, 2001)
"This communication represents the definitive report of a randomized phase III study comparing cisplatin and carboplatin, in combination with vindesine and mitomycin C in stage IIIB and IV squamous-cell bronchogenic carcinoma."	2.70	Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. ( Babović, N; Elezar, E; Gavrilović, D; Jelić, S; Kovacević, S; Kovcin, V; Mitrović, L; Radosavljević, D; Radulović, S; Tomasević, Z, 2001)
" However, the degree of toxicity was limited in our trial and therefore attempts to increase the dosage and/or revise the administration schedule for cancer of the pharynx and T1 to T3 tumor disease appear warranted."	2.69	Survival results of neoadjuvant chemotherapy for advanced squamous cell carcinoma of the head and neck. ( Ikari, T; Kano, S; Kawaida, M; Kawaura, M; Kohno, N; Nakamizo, M; Tanaka, K, 2000)
"Between March 1991 and October 1993, 49 patients with inoperable head and neck carcinoma were randomly assigned to receive either radiation therapy alone (group A) or radiotherapy combined with simultaneous application of Mitomycin C and Bleomycin (group B)."	2.68	Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report. ( Budihna, M; Furlan, L; Lesnicar, H; Rudolf, Z; Smid, L; Soba, E; Zakotnik, B; Zargi, M, 1995)
"N&V and leukopenia were the major side effects."	2.68	Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer. ( Ichikawa, G; Inuyama, Y; Kawaida, M; Kohno, N; Ohnuma, T; Shirasaka, T, 1995)
"Twenty one patients with resectable oral cancer received two courses of induction chemotherapy with peplomycin (PEP), vincristine (VCR), mitomycin C (MMC) and cisplatin (CDDP)."	2.68	[Clinical and histological effect of induction chemotherapy with peplomycin, vincristine, mitomycin C and cis-platinum on oral squamous cell carcinomas]. ( Hayashido, Y; Hiranuma, T; Matsuya, T; Mima, T; Ogura, T; Sakai, T; Shirasuna, K; Usui, M, 1995)
"12."	2.68	Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. ( Kimura, H; Yamaguchi, Y, 1995)
"Thirty-one patients with squamous cell carcinoma of the vulva were treated with two courses of combination chemotherapy mitomycin C, 15 mg/m2 intravenously (i."	2.68	Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. ( di Re, F; Fontanelli, R; Kenda, R; Lupi, G; Paladini, D; Raspagliesi, F; Zucali, R, 1996)
"All patients had verified squamous cell carcinoma and were referred for primary radiation therapy."	2.68	Conventional vs accelerated fractionation in head and neck cancer. ( Dobrowsky, E; Dobrowsky, W; Grasl, M; Kautzky, M; Köhler, W; Millesi, W; Naudé, J; Pavelka, R; Reichel, M; Wilson, GD, 1996)
"Patients with residual tumor on posttreatment biopsy were treated with a salvage regimen that consisted of additional pelvic RT (9 Gy), 5-FU, and cisplatin (100 mg/m2)."	2.68	Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. ( Coia, L; Doggett, S; Flam, M; John, M; Kerman, H; Murray, K; Myerson, R; Pajak, TF; Petrelli, N; Quivey, J; Rotman, M, 1996)
"porfiromycin, there have been no statistically significant differences between the two arms with respect to white blood cell count (WBC), platelet, or hemoglobin nadirs."	2.68	Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. ( Fischer, D; Fischer, JJ; Haffty, BG; Papac, R; Rockwell, S; Ross, D; Sartorelli, AC; Sasaki, CT; Son, YH; Wilson, LD, 1997)
"Neo-adjuvant therapy with MIC in squamous carcinoma of the oesophagus has shown encouraging early results, with acceptable toxicity."	2.67	A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus. ( Allen, SM; Cullen, MH; Darnton, SJ; Duffy, JP; Matthews, HR; Walker, SJ, 1994)
"Mitomycin C has antitumor activity against squamous cell lung carcinoma when used alone or in combination with MVP."	2.67	A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. ( Dalton, RJ; Etzell, PS; Foley, JF; Jett, JR; Kardinal, CG; Mailliard, JA; Maksymiuk, AW; Marschke, RF; Su, JQ; Veeder, MH, 1992)
"Although histology (squamous vs."	2.67	Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and post-recurrent survival. ( Aso, H; Hara, N; Ichinose, Y; Kuda, T; Motohiro, A; Ohta, M, 1991)
"Twenty-five patients with cervical cancer (4 post-operative cases with FIGO stage Ib or IIb, 2 with stage IV, and 19 recurrence) were treated with a new BOMP consisting of bleomycin (5 mg/body, drip, i."	2.67	[Treatment of advanced or recurrent cervical cancer by a new BOMP regimen consisting of bleomycin, vincristine, mitomycin-C, and low-dose consecutive cisplatin]. ( Chen, JT; Fujimoto, I; Koi, S; Nakayama, K; Seimiya, Y; Shimizu, Y; Teshima, H; Yamakawa, Y; Yamauchi, K; Yokosuka, K, 1991)
"Twenty-seven pts with squamous cell carcinoma were randomized between regimen PMP (CDDP 60 mg/m2, d 1, MMC 6 mg/m2, d 3, d 10 and PEP 5 mg/m2, d 3-7) and regimen PM (CDDP 60 mg/m2, d 1 and MMC 6 mg/m2, d 3, d 10)."	2.66	[A randomized trial with various combinations of cis-platinum (CDDP), mitomycin C (MMC), peplomycin (PEP) and ftorafur (FT) in the treatment of non-small cell lung cancer]. ( Abe, S; Miyamoto, H; Nakabayashi, T; Ohosaki, Y; Yasuda, S, 1986)
" During the past eleven years, we have used postoperative chemotherapy in three ways over three different periods: in the earliest period, short-term combined chemotherapy (STCC) was used, in the middle period, intermittent long-term combined chemotherapy (ILTCC) was used in combination with immunotherapy for a randomized group, and in the latest period, when continuous long-term combined chemotherapy (CLTCC) with immunotherapy was employed."	2.66	[Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy]. ( Hashizume, Y; Ichihashi, T; Iida, S; Kimoto, H; Kobayashi, H; Sato, H; Shimizu, J; Tsunamura, Y; Watanabe, Y; Yamada, T, 1985)
" Management of these adverse effects is reviewed, as are future directions in anal cancer treatment and their impact on toxicity."	2.55	Evolution and Management of Treatment-Related Toxicity in Anal Cancer. ( Czito, BG; Kachnic, LA; Ludmir, EB, 2017)
"Xeroderma pigmentosum is a rare genetic disorder associated with various ocular malignancies."	2.53	Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature. ( Kalamkar, C; Mukherjee, A; Radke, N; Radke, S, 2016)
"Rectal squamous cell carcinoma is a rare tumour; it management should be based on anal curative and conservative intent chemoradiation."	2.53	[Rectal squamous cell carcinoma treatment: Retrospective experience in two French university hospitals, review and proposals]. ( Bosset, JF; Huguet, F; Loganadane, G; Schernberg, A; Servagi-Vernat, S; Touboul, E, 2016)
"The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage."	2.52	Anal cancer treatment: current status and future perspectives. ( Abdayem, P; Antoun, J; Ghosn, M; Kourie, HR; Nasr, D, 2015)
"Although anal canal squamous cell carcinoma is rare, the general practitioner should consider this diagnosis in a patient with persistent lower abdominal symptoms."	2.47	[Management of anal canal carcinoma]. ( Betz, M; Cochet, S; George, AC; Roth, A; Thang, NN, 2011)
"We report a case with perianal squamous cell carcinoma, which showed a complete response more than five years after chemoradiotherapy."	2.47	[A case of perianal squamous cell carcinoma attaining a complete response over five years with chemoradiotherapy]. ( Imada, S; Ishikawa, O; Kishi, K; Miyashiro, I; Motoori, M; Nishiyama, K; Noura, S; Ohue, M; Shingai, T; Yano, M, 2011)
"The role of cisplatin in anal cancer is not completely clear, although an ongoing randomized trial (Anal Cancer Trial II) may help clarify the role of cisplatin."	2.44	Current treatment for localized anal carcinoma. ( Ajani, JA; Crane, CH; Das, P, 2007)
"Advanced squamous cell carcinomas of the oral cavity, oro-, hypopharynx and larynx often have to be categorised as non resectable disease."	2.43	[Decision making in non resectable head and neck tumours]. ( Dietz, A; Dollner, R; Hildebrandt, G; Weber, A, 2005)
"During the past two decades, anal cancer has served as a paradigm for the successful application of chemoradiation to solid tumours; so far, it remains one of the few carcinomas of the gastrointestinal tract which are curable without the need for definitive surgery."	2.42	Chemotherapeutic options in the management of anal cancer. ( Allal, AS; Gervaz, P; Morel, P; Roth, A, 2004)
"Mitomycin C and 5 FU were delivered on weeks 1 and 5 of the irradiation."	2.41	[Radiochemotherapy in anal canal epidermoid cancer]. ( Peiffert, D, 2000)
"Chest X-rays and CT scans revealed atelectasis of the right middle lobe."	2.41	A solitary bronchial papilloma with malignant changes. ( Inoue, Y; Ishii, H; Ito, M; Ito, T; Kimino, K; Kishikawa, M; Kohno, S; Nakashima, M; Oka, M, 2001)
"Five-year survival rates were 57% for squamous cell carcinoma, 63% for adenocarcinoma, and 33% for melanoma."	2.40	Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. ( Klas, JV; Madoff, RD; Rothenberger, DA; Wong, WD, 1999)
"We present an additional case of rectal squamous cell carcinoma (SCC) complicating chronic ulcerative colitis in a 33-year-old woman who had the disease for 15 years."	2.39	Squamous cell carcinoma complicating idiopathic inflammatory bowel disease. ( Butler, B; Doerr, R; Kulaylat, MN; Satchidanand, SK; Singh, A, 1995)
"Management of the superficial bladder cancer patient consists of two complementary but separate therapeutic goals: treatment of the existing tumor(s) and prevention of tumor recurrence."	2.37	The biology and treatment of superficial bladder cancer. ( Lum, BL; Torti, FM, 1984)
"International guidelines regarding the treatment of squamous cell carcinoma of the anus (SCCA) recommend intensity-modulated radiotherapy (IMRT) combined with mitomycin-based chemotherapy (CT)."	1.91	Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE. ( Baba-Hamed, N; Crehange, G; Diaz, O; Drouet, F; Hautefeuille, V; Hummelsberger, M; Larrouy, A; LE Malicot, K; Lemanski, C; Lepage, C; Lievre, A; Menager-Tabourel, E; Minsat, M; Mornex, F; Peiffert, D; Pommier, P; Quero, L; Regnault, P; Rivin Del Campo, E; Ronchin, P; Saint, A; Tougeron, D; Vendrely, V; Zasadny, X, 2023)
"Our results suggest IMRT-based CRT with concurrent fluoropyrimidine and cisplatin is a safe and feasible option for patient with SCCA and may cause less acute toxicity."	1.72	Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. ( Bednarski, BK; Chang, GJ; Das, P; Delclos, ME; Eng, C; Holliday, EB; Jennings, K; Johnson, B; Koay, EJ; Koong, AC; Ludmir, EB; Messick, CA; Minsky, BD; Morris, VK; Rodriguez-Bigas, MA; Skibber, JM; Smith, GL; Taniguchi, C; Tillman, MM; You, YN, 2022)
"Anal cancer is a rare disease that has doubled in incidence over the last four decades."	1.62	Molecular and genomic characterisation of a panel of human anal cancer cell lines. ( Behrenbruch, CC; Bernardi, MP; Chittleborough, TJ; Di Costanzo, N; Guerra, GR; Hawkes, D; Haynes, NM; Heriot, AG; Kong, JC; Liu, DS; Lupat, R; Millen, RM; Mitchell, C; Ngan, SY; Phillips, WA; Ramsay, RG; Read, M; Roth, S; Sampurno, S; Sia, J; Teh, J; Tothill, RW; Xu, H; Yu, J, 2021)
"Anal squamous cell carcinoma has rarely been reported in the setting of ulcerative colitis."	1.62	Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols? ( Click, B; Hull, TL; Lightner, AL; McMichael, J; Regueiro, M; Steele, SR; Vaidya, P, 2021)
"BACKGROUND Conjunctival squamous cell carcinoma is the most common non-pigmented malignancy of the ocular surface."	1.56	Clinical Management of Squamous Cell Carcinoma of the Conjunctiva. ( Bartz-Schmidt, KU; Bösmüller, HC; Bramkamp, M; Milla, J; Röck, D; Röck, T, 2020)
"Acute hematotoxicity (G3, 4, 5 according to Common Terminology Criteria for Adverse Events - CTCAE) was significantly associated with the concomitant chemoradiotherapy (P = 0."	1.56	Haematotoxicity in IMRT/VMAT curatively treated anal cancer. ( Drbohlavová, T; Jirkovská, M; Lohynská, R; Malinová, B; Mazaná, E; Nýdlová, A; Stankušová, H; Veselský, T, 2020)
"Bovine ocular squamous cell carcinoma (BOSCC) also called cancer eye, represents the most economically important neoplasm in large animals."	1.56	Efficacy of BCG vaccine and Mitomycin C for the treatment of ocular squamous cell carcinoma in bovines. ( Devalam, RP; Podarala, V; Prasanna Lakshmi, M; Venkata, SKR, 2020)
"Metastatic squamous cell carcinomas (SCC) of the anal canal are rare and there is no international consensus on their second-line management."	1.51	Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal. ( Benezery, K; Cavaglione, G; Evesque, L; Falk, AT; Francois, E; Montagne, L; Saint, A, 2019)
"For 70 women with anal cancer treated at our department, acute and chronic side effects and quality of life (QoL) were evaluated with questionnaires using the Common Terminology Criteria for Adverse Events (CTCAE v."	1.51	Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. ( Adeberg, S; Debus, J; Haefner, MF; Herfarth, K; Koerber, SA; Krug, D; Liermann, J; Seither, B; Slynko, A; Sterzing, F, 2019)
"Squamous cell carcinoma is the most common malignant tumor of the bulbar conjunctiva."	1.51	[Management of squamous cell carcinoma of the conjunctiva in a young patient: Case report]. ( Abdou, T; Benhadouch, R; Dib, S, 2019)
"Ninety-seven patients with oral squamous cell carcinoma, treated preoperatively with radiotherapy in combination with chemotherapy or cetuximab, were included in this retrospective analysis."	1.48	P16 positivity and regression grade predict survival after neoadjuvant radiotherapy of OSCC. ( Eder-Czembirek, C; Fuereder, T; Selzer, E; Sulzbacher, I, 2018)
" Patient acute gastrointestinal toxicity was recorded using Common Terminology Criteria of Adverse Events (CTCAE) diarrhoea grading."	1.48	Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. ( Amor, H; Blakey, D; Chao, M; Guerrieri, M; Guiney, M; Ho, H; Macleod, C; Melven, L; Ng, M; Skelton, J; Subramanian, B, 2018)
"Grade 3-4 neutropenia was seen in 10/23 patients (43%)."	1.46	PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. ( Beer, J; Bodis, S; Oehler, C; Vlachopoulou, V; von Moos, R; Zimmermann, M; Zwahlen, DR, 2017)
"Stage IV squamous cell carcinoma of the anus outcomes are poor, but first-line chemotherapy can enable good response rates."	1.46	Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. ( Benezery, K; Cavaglione, G; Doyen, J; Evesque, L; Follana, P; François, E; Reure, J; Tuan Falk, A, 2017)
"The aim of the study is to evaluate the long-term clinical results of amniotic membrane transplantation (AMT) combined with mitomycin C (MMC) for reconstruction of conjunctival defects created during the excision of ocular surface squamous neoplasia (OSSN)."	1.46	Long-term outcome of amniotic membrane transplantation combined with mitomycin C for conjunctival reconstruction after ocular surface squamous neoplasia excision. ( Hanada, K; Miyokawa, N; Nishikawa, N; Yoshida, A, 2017)
"Oral squamous cell carcinoma (OSCC) may develop in young adults."	1.43	Sensitivity to chromosomal breakage as risk factor in young adults with oral squamous cell carcinoma. ( Braakhuis, BJ; Brakenhoff, RH; Flach, GB; Graveland, AP; Joenje, H; Leemans, CR; Nieuwint, AW; Oostra, AB, 2016)
"However, anal cancers are rare in patients with HIV in Japan."	1.43	[Squamous cell carcinoma of the anal canal treated with chemoradiotherapy in a patient with HIV]. ( Ishida, H; Mita, E; Mori, K; Nakazuru, S; Nishio, K; Sakakibara, Y; Sugimoto, A; Uehira, T; Yajima, K; Yamada, T, 2016)
"Anal cancer was diagnosed in a 36-year-old nulliparous woman."	1.43	Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level. ( Biel, P; Cordes, T; Köhler, C; Marnitz, S, 2016)
"At 4 years of follow-up, no recurrence has been noted."	1.42	Bilateral recurrent ocular surface squamous cell cancer associated with epidermodysplasia verruciformis. ( Arora, T; Sharma, N; Sharma, S; Titiyal, JS, 2015)
"Anal cancer is uncommon."	1.42	Review of anal cancer patients at the Ottawa hospital. ( Abunassar, M; Asmis, T; Jonker, DJ; Reinders, J, 2015)
"Grade 2 anorexia was the most frequent chemotherapy-related toxicity and no toxic death was noted."	1.40	Intraarterial chemotherapy as the first-line therapy in penile cancer. ( Chen, CH; Chiang, PH; Shen, YC, 2014)
"Capecitabine is an established treatment alternative to intravenous 5-fluorouracil (5-FU) for patients with rectal cancer receiving chemoradiotherapy."	1.40	Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. ( Beijnen, JH; Cats, A; Dewit, L; Meulendijks, D; Schellens, JH; Tomasoa, NB; van Tinteren, H, 2014)
" Toxicity was graded with the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3."	1.40	Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. ( Bayley, AJ; Brierley, J; Chen, EX; Cho, C; Craig, T; Cummings, BJ; Dawson, LA; Dinniwell, R; Easson, AM; Han, K; Kassam, Z; Kim, J; Krzyzanowska, MK; Le, LW; Lindsay, P; Moore, MJ; Ringash, J; Skliarenko, J; Wong, R, 2014)
"Two of eight patients (25 %) with squamous cell carcinoma (SCC) had positive lateral margins."	1.39	Combined excision, cryotherapy, and intraoperative mitomycin C (EXCRIM) for localized intraepithelial and squamous cell carcinoma of the conjunctiva. ( Arvas, S; Pazarli, H; Sarici, AM, 2013)
"The treatment of anal cancer is based on concomitant radiotherapy and chemotherapy and is associated with a nonnegligible rate of local severe toxicities that can strongly impair the quality of life."	1.39	Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. ( Benezery, K; Doyen, J; Follana, P; Francois, E; Gal, J; Gérard, JP; Hannoun-Levi, JM; Ortholan, C, 2013)
"Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity."	1.38	Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. ( Blaszkowsky, LS; Coen, JJ; Hartshorn, K; Hong, TS; Kachnic, LA; Kwak, EL; Ryan, DP; Tsai, HK; Willins, JD, 2012)
"CRT is a highly effective approach in anal cancer."	1.38	Twenty-five-year experience with radical chemoradiation for anal cancer. ( Chander, S; Chu, J; Foo, M; Heriot, A; Lee, MT; Leong, T; Link, E; Lynch, CA; Mackay, J; Michael, M; Ngan, SY; Tomaszewski, JM; Tran, P; Vazquez, M, 2012)
"Data of all patients diagnosed with squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the oesophagus, treated between 1983 and 2007 in the department of radiation oncology of the LMU, were obtained."	1.38	Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre. ( Belka, C; Hölzel, D; Schmidt, M; Wolf, MC; Zehentmayr, F, 2012)
"Pre- and post-treatment staging of anal cancer are often inaccurate."	1.38	Role of positron emission tomography-computed tomography in the management of anal cancer. ( Baccega, M; Bellò, M; Cassoni, P; Cravero, F; Filippini, C; Fora, G; Lesca, A; Milanesi, E; Mistrangelo, M; Morino, M; Munoz, FH; Pelosi, E; Racca, P; Ricardi, U; Skanjeti, A, 2012)
"The patient is staged as having T2N3 squamous cell carcinoma of the anal canal (Table 1)."	1.38	Mitomycin in anal cancer: still the standard of care. ( Chin, JY; Hong, TS; Ryan, DP, 2012)
"To update our experience in treating squamous cell carcinoma of the anal margin with definitive radiotherapy (RT)."	1.37	Squamous cell carcinoma of the anal margin: the university of Florida experience. ( Balamucki, CJ; George, TJ; Kirwan, JM; Mendenhall, WM; Morris, CG; Newlin, HE; Rout, WR; Zlotecki, RA, 2011)
"He was diagnosed with conjunctival squamous cell carcinoma and treated with topical mitomycin C (MMC)."	1.37	Herpes keratitis in a patient undergoing treatment with topical mitomycin C. ( Amorese, L; Foster, S; Gonzalez-Gonzalez, LA; Shaikh, M; Siddique, SS, 2011)
"Mitomycin C (MMC) was applied to the area at a dose of 0."	1.37	Periocular allergic contact dermatitis following topical Mitomycin C eye drop application. ( Cavdar, M; Cumurcu, T; Sener, S, 2011)
"It includes 51 cases of squamous cell carcinoma, 6 cases of adenocarcinoma and 1 case of adenosquamous carcinoma."	1.37	[Evaluation of the efficacy of bronchial arterial infusion chemotherapy for the treatment of central non-small cell lung cancer]. ( Chen, Y; Li, H; Liu, DZ; Yan, D; Zeng, HY; Zhou, CW, 2011)
"Mitomycin-C (MMC) is a first-line therapy for anal squamous cell carcinoma (ASCC), and it continues to be used for several other indications."	1.37	Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. ( Chu, E; El-Ghazal, R; Marks, P; Podoltsev, N; Saif, MW, 2011)
"Eighty-four patients with invasive anal cancer treated with definitive external beam radiotherapy (RT) with a mandatory split of 12 days (52 patients, Montreal, Canada) or without an intended split (32 patients, Zurich, Switzerland) were reviewed."	1.36	Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature. ( Bahary, JP; Ciernik, IF; Donath, D; Lütolf, UM; Oehler, C; Provencher, S, 2010)
"From 1991 to 2005, 58 patients with anal cancer were curatively treated with CRT."	1.36	Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. ( Donath, D; Fortin, B; Jolicoeur, M; Lavertu, S; Oehler, C; Provencher, S, 2010)
"298 patients with inoperable cancer of the esophagus were identified (16."	1.36	Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. ( Belka, C; Ganswindt, U; Haimerl, W; Hölzel, D; Niyazi, M; Schmidt, M; Wolf, M; Zehentmayr, F, 2010)
"HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries."	1.36	Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. ( Ennis, RD; Evans, A; Grossbard, M; Hauerstock, D, 2010)
"We report three cases of anal canal squamous cell carcinoma treated with radiotherapy combined with S-1 and mitomycin C(MMC)."	1.36	[Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas]. ( Akaike, M; Motohashi, O; Nakayama, N; Nakayama, Y; Nishimura, K; Nonaka, T; Shiozawa, M; Takagi, S; Yoshii, T, 2010)
"We report a case of squamous cell carcinoma of the anus with associated HIV infection."	1.36	[A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. ( Fujitani, K; Hirao, M; Ikenaga, M; Mishima, H; Miyamoto, A; Miyazaki, M; Nakamori, S; Omiya, H; Sueda, K; Takami, K; Tsujie, M; Tsujinaka, T; Yasui, M; Yoshida, K, 2010)
"Leukemias and squamous cell carcinomas (SCCs) are the most predominant FA-associated cancers, with the latter exhibiting markedly early disease onset and aggressiveness."	1.35	Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. ( Cha, E; Duensing, S; Higginbotham, JM; Hoskins, EE; Kelly, P; Morris, TA; Spardy, N; Wells, SI; Wikenheiser-Brokamp, KA; Williams, DA, 2009)
"Pure primary squamous cell carcinoma (SCC) of the breast is rare and difficult to treat."	1.35	Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy. ( Bhatt, L; Fernando, I, 2009)
"Primary corneal squamous cell carcinoma with no history of keratoconjunctivitis sicca is rare in dogs."	1.35	Superficial keratectomy and topical mitomycin C as therapy for a corneal squamous cell carcinoma in a dog. ( Karasawa, K; Matsuda, H; Tanaka, A, 2008)
"To report a case of isolated squamous cell carcinoma of cornea."	1.35	Squamous cell carcinoma of cornea. ( Arya, SK; Gupta, H; Gupta, S; Malik, A; Samra, SG; Sood, S, 2008)
"Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation."	1.33	The bottom line: outcomes after conservation treatment in anal cancer. ( Dwyer, MK; Gebski, VJ; Jayamohan, J, 2006)
"To determine the efficiency of topical cyclosporine-A (CSA) combined with mitomycin C (MMC) as an adjunctive treatment in diffuse conjunctival and corneal squamous cell carcinoma (CCSC)."	1.33	Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma. ( Erbilen, E; Tunc, M, 2006)
"The patient was first diagnosed with squamous cell carcinoma of the anus 1 year before admission."	1.32	Cases from the Osler Medical Service at Johns Hopkins University. ( Brown, C; Zetola-Burneo, N, 2004)
"Patients with advanced stage invasive cervical cancer (CC) exhibit highly complex genomic alterations and respond poorly to conventional treatment protocols."	1.32	Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. ( Arias-Pulido, H; Basso, K; Dürst, M; Gissmann, L; Mansukhani, M; Meyer, L; Murty, VV; Nandula, SV; Narayan, G; Pothuri, B; Schneider, A; Sugirtharaj, DD; Vargas, H; Villella, J, 2004)
"A complete remission of anal cancer was achieved in both patients with minimal acute and late toxicities."	1.31	Successful chemoradiotherapy for anal cancer despite previous radical radiotherapy for gynaecological malignancy. ( Arnott, SJ; Leslie, MD; Subramaniam, R, 2002)
"In patients with pancreatic cancer, the overall response rate was 42% with a median survival of 8 months."	1.31	Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. ( Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P, 2002)
"Multiple endobronchial squamous cell carcinoma is sometimes difficult to resect due to poor pulmonary function."	1.31	Induction chemotherapy before operation for multiple endobronchial squamous cell carcinoma of the lung. ( Hayashi, E; Huang, CL; Kameyama, K; Liu, D; Okamoto, T; Yamamoto, Y; Yokomise, H, 2002)
"In p53 wild-type MCF-7 breast carcinoma cells, the cyclin-dependent kinase inhibitor protein p21/WAF1 was markedly induced after the treatment with MMC alone, although this response was significantly delayed from the time of MMC treatment."	1.31	UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. ( Akinaga, S; Akiyama, T; Eastman, A; Shimizu, M; Sugiyama, K; Takahashi, R; Tamaoki, T; Yamaguchi, K, 2000)
"The effect of the treatment of anal cancer by performing a high-dose-rate (HDR) brachytherapy boost during a short split between the external beam radiotherapy series (EBR) +/- chemotherapy was investigated."	1.31	Experience with split-course external beam irradiation +/- chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal. ( Berger, A; Gebhart, FH; Geyer, E; Hebenstreit, J; Kapp, KS; Oechs, AC; Stoeger, H, 2001)
"The potential of Mitomycin C in combination with fractionated irradiation to inhibit tumour cell repopulation of a fast growing squamous cell carcinoma after fractionated radiotherapy was investigated in vivo."	1.31	Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. ( Bamberg, M; Belka, C; Budach, W; Classen, J; Marini, P; Paulsen, F; Scheithauer, H; Welz, S, 2002)
"We observed euploid DNA-polyploidy and cytomorphological changes in all patients (19/19)."	1.31	Topical mitomycin C and radiation induce conjunctival DNA-polyploidy. ( Böcking, A; Cartsburg, O; Hillenkamp, J; Kallen, C; Pomjanski, N; Sundmacher, R, 2001)
"The subject was a patient who had squamous cell carcinoma in the pudendum and the inguinal region (12."	1.30	[A case of FIGO stage IV A vulvar cancer successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)]. ( Narimatsu, A; Okada, O, 1997)
"Pretreatment with tirapazamine, a bioreductive agent, could enhance the sensitivity of tumor cells, including Q cells, to radiation more markedly than mitomycin C pretreatment as judged from an in vivo assay immediately after irradiation."	1.30	Effects of bioreductive agents, tirapazamine and mitomycin C, on quiescent cell populations in solid tumors, evaluated by micronucleus assay. ( Akaboshi, M; Hori, H; Kinashi, Y; Masunaga, S; Ono, K; Shibata, T; Suzuki, M; Takagaki, M, 1997)
"The response rate was higher in squamous cell carcinomas (85%) than adenocarcinomas or adenosquamous carcinomas (67%)."	1.30	[Neoadjuvant chemotherapy for advanced cervical cancer]. ( Hongo, A; Ikuhashi, H; Kobashi, Y; Kodama, J; Kudo, T; Miyagi, Y; Mizutani, Y; Okuda, H; Yoshinouchi, M, 1999)
" To explain this tumor selectivity, the distribution of FK317 was investigated after dosing tumor-bearing mice with the 14C-labelled compound."	1.30	FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice. ( Fujiwara, T; Inami, M; Kawamura, I; Manda, T; Matsumoto, S; Naoe, Y; Nishigaki, F; Shimomura, K; Takagaki, S; Tsujimoto, S; Yamazaki, S, 1998)
"DNA cytometry showed nonaneuploidy in all of these."	1.30	Cytologic and DNA cytometric diagnosis and therapy monitoring of squamous cell carcinoma in situ and malignant melanoma of the cornea and conjunctiva. ( Böcking, A; Kersten, A; Krallmann, R; Motherby, H; Nadjari, B; Ross, B; Sundmacher, R, 1999)
"Patients with locally advanced squamous cell carcinoma of the bulbomembranous urethra fare poorly whether they undergo surgery or primary radiotherapy."	1.29	Combined chemoradiotherapy for locally advanced squamous cell carcinoma of the bulbomembranous urethra: a case report. ( Huang, DT; Lutz, ST, 1995)
"The standard treatment for anal cancer is combination chemo-radiotherapy."	1.29	The influence of age on the management of anal cancer. ( Basrur, V; de Gara, CJ; Figueredo, A; Goodyear, M; Knight, P, 1995)
"Histologically, aneuploidy was detected in 71."	1.29	[Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck]. ( Miyagi, M; Nakashima, T; Soda, T, 1994)
"Seven oesophageal squamous carcinomas, treated with pre-operative chemotherapy (mitomycin-C, ifosfamide and cisplatin-MIC), with a course finishing 21 days prior to resection, were examined by electronmicroscopy."	1.29	Effects of chemotherapy on ultrastructure of oesophageal squamous cell carcinoma. ( Antonakopoulos, GN; Darnton, SJ; Duffy, JP; Matthews, HR; Newman, J, 1994)
"Four hundred five patients with anal cancer were identified by computer search, and 204 (51%) were evaluable; 164 of 204 (80%) had squamous cell carcinoma, 137 of whom (84%) were treated with sphincter-preserving procedures, and 27 of whom (16%) were treated by by radical surgery."	1.29	Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. ( Coplin, MA; Johnson, FE; Longo, WE; Vernava, AM; Virgo, KS; Wade, TP, 1994)
"Among them, three patients had acquired immunodeficiency syndrome (AIDS)."	1.29	Squamous-cell carcinoma of the anus in HIV-positive patients. ( Berson, A; Chadha, M; Malamud, S; Pisch, J; Rosenblatt, EA, 1994)
" Pelvic irradiation was administered by external beams (6 Mv), for a 50-Gy dosage (200 cGy/day for 5 weeks); in 4 cases treatment was completed by means of brachytherapy (192 Ir), with 20-25 Gy dosage."	1.29	[Loco-regional intra-arterial chemotherapy combined with radiotherapy in cervical carcinoma]. ( Raffetto, N; Salvatori, F; Trinci, C; Trinci, M, 1993)
" There was a significant correlation between the area under the time versus concentration curve (AUC) of MMC and the age of patients (r = 0."	1.28	Pharmacokinetic study of mitomycin C with emphasis on the influence of aging. ( Karato, A; Miya, T; Saijo, N; Sasaki, Y, 1992)
" SOD-POE did not influence the antitumor effects of ADR and MMC either in vitro or in vivo, but prevented the toxic death of BALB/c, nu/nu male mice caused by overdoses of ADR or MMC."	1.28	Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C. ( Akiyama, S; Dohmitsu, K; Ito, K; Kataoka, M; Kawasaki, S; Kondoh, K; Kurokawa, T; Sugiyama, S; Watanabe, T; Yamauchi, M, 1992)
"SPG also inhibited the pulmonary metastasis of NR-S1 tumor after radiotherapy."	1.28	Combination therapy of radiation and Sizofiran (SPG) on the tumor growth and metastasis on squamous-cell carcinoma NR-S1 in syngeneic C3H/He mice. ( Amemiya, K; Arika, T; Nomoto, K, 1992)
"Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2."	1.28	Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991)
"Eighty patients with Stage III and IV head and neck cancer were treated with a four-drug regimen consisting of bleomycin, vincristine, methotrexate, and mitomycin-C (BOMM regimen)."	1.28	BOMM regimen for the treatment of advanced head and neck carcinoma. ( Inuyama, Y; Kohno, N; Ohnuma, T; Sakurai, S, 1991)
"There are few reports about the methods, amounts, and kinds of dosage about intermittent intra-arterial chemotherapy of liver metastases from primal pathological type's squamous cell carcinoma."	1.28	[Study of intermittent intra-arterial infusion chemotherapy in liver metastases from squamous cell carcinoma]. ( Aoki, T; Kasuya, K; Kimura, K; Koyanagi, Y; Ozawa, T; Sato, S; Tsuchida, A; Yasuda, D; Yoshimatsu, A, 1991)
"A total of 10 uterine cervical cancer patients (stage IIb 2, stage IIIb 6, stage IVb 2) were treated two times with selective intra-arterial injection of combined drugs of CDDP, ADR, 5-FU, MMC before operation or radiation therapy."	1.28	[Transcatheter intra-arterial injection of combination drugs in case of advanced uterine cervical cancer]. ( Abe, M; Honda, T; Kinashi, Y; Mori, T; Nagata, Y; Tai, S; Takai, I, 1990)
"The effect on squamous cell carcinoma was more prominent than on other cell types."	1.28	Reappraisal of bronchial arterial infusion therapy for advanced lung cancer. ( Iwa, T; Kitagawa, M; Matsubara, F; Mizukami, Y; Murakami, S; Nonomura, A; Shimizu, J; Tsubota, M; Watanabe, Y; Yoshida, M, 1990)
"Histologically, 16 had squamous cell carcinoma, 11 adenocarcinoma, 3 small cell anaplastic carcinoma and 1 un-classified cancer."	1.28	[Bronchial arterial infusion chemotherapy with or without radiotherapy for advanced lung cancer]. ( Huang, DP, 1990)
"Twenty-three patients with gynecologic squamous cell carcinomas (20 cervical, 2 vulvar, 1 ovarian) were treated with bleomycin, vincristine, mitomycin-C, and cis-platinum."	1.28	Bleomycin, vincristine, mitomycin C, and cis-platinum in gynecologic squamous cell carcinomas: a high incidence of pulmonary toxicity. ( Chambers, JT; Chambers, SK; Del Prete, SA; Flynn, SD; Schwartz, PE, 1989)
"A 62-year-old female with anal cancer underwent Miles operation in November, 1987."	1.28	[Effects of intra-arterial infusion chemotherapy in local recurrence of anal cancer]. ( Amino, K; Mieno, K; Miura, S; Satoi, Y; Shikata, J; Takeda, Y, 1989)
"Of 25 patients with squamous cell carcinoma, 13 underwent esophagectomy."	1.28	Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma. ( Daniel, TM; Hahn, SS; Harkins, BJ; Stewart, FM, 1989)
"Thirty-three patients with advanced cervical cancer (31 squamous cancer, two adenosquamous cancer) previously untreated with cytotoxic drugs, were treated with bleomycin, 5 mg daily, for seven days and mitomycin C, 10 mg, on day 8."	1.27	Bleomycin-mitomycin C in advanced carcinoma of the cervix. A third look. ( Gullberg, B; Johnsson, JE; Mattsson, W; Sigurdsson, K; Simonsen, E; Stendahl, U; Tropé, C, 1983)
"Lymphocytes from patients with squamous cell carcinoma, large cell carcinoma and carcinoid exhibited positive activity levels of 11."	1.27	Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor. ( Fujisawa, T; Kadoyama, C; Kimura, H; Sato, N; Yamaguchi, Y, 1983)
"Of 55 patients with esophageal squamous cell carcinoma, 30 with localized disease were treated with a combined modality for curative intent."	1.27	Combined modality therapy for esophageal squamous cell carcinoma. ( Asfaw, I; Franklin, R; Hoschner, J; Loh, J; Miller, P; Rosenberg, J; Steiger, Z; Vaishampayan, G, 1983)
" After determination of dose-response relationships and toxicity, treated tumours were biopsied at different times and cell cycle distribution pattern, 3HTdR incorporation into DNA, histology and tumour volume were recorded."	1.27	Cell cycle perturbations in heterotransplanted squamous-cell carcinoma of the head and neck after mitomycin C and cisplatin treatment. ( Alm, P; Biörklund, A; Killander, D; Långström, E; Tropé, C; Wennerberg, J, 1984)
"Metronidazole, 1."	1.27	Feasibility study of combining metronidazole with chemotherapy. ( Bélanger, R; Crook, AF; Heringer, R; Hopkins, HS; Hugenholtz, H; Maroun, JA; Richard, MT; Stewart, DJ; Yan, RC; Young, V, 1983)
"Twenty women with recurrent squamous cell carcinoma of the cervix were treated with bleomycin followed by adriamycin and mitomycin-C."	1.27	Assessment of bleomycin, adriamycin and mitomycin-C in the treatment of recurrent cervical cancer. ( Blackledge, G; Chan, KK; Lawton, FG; Luesley, DM; Meanwell, CA; Mould, JJ; Perren, TJ, 1985)
"Twenty-one consecutive patients with squamous cell carcinoma of the esophagus (EC) were referred, with advanced Stage III disease in nine patients, severe pulmonary/cardiac disease in five patients, and postsurgical recurrences or metastatic disease in seven patients."	1.27	Inoperable esophageal carcinoma: results of aggressive synchronous radiotherapy and chemotherapy. A pilot study. ( Flam, M; John, M; Mowry, PA; Wittlinger, P, 1987)
"Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2."	1.27	Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. ( Coia, LR; Engstrom, PF; Paul, A, 1987)
"Ten patients with advanced squamous cell carcinoma of the uterine cervix received induction chemotherapy with cis-platinum, mitomycin-C, vincristine, and bleomycin (BOMP) over a 5 week period, followed by radiotherapy with concomitant weekly cisplatinum."	1.27	Combined chemotherapy and radiation therapy for advanced carcinoma of the cervix. ( Bloomer, WD; Cohen, C; Dalton, JF; Dottino, P; Goodman, HM; Kredentser, D; Lipsztein, R, 1987)
"In case 1, a 73-year-old female with squamous cell carcinoma was successfully treated with irradiation of 4,000 rad and peplomycin of 60 mg intravenously given."	1.27	[Female urethral carcinoma: results of irradiation in 2 patients]. ( Kanai, S; Kondo, A; Miyake, K; Okamura, K; Otani, T; Sahashi, M; Saitoh, M; Sakakibara, T; Shimozi, T; Takashi, M, 1988)
"Twenty-one patients with squamous carcinoma of the genital tract were treated with bleomycin, Oncovin, mitomycin-C, and cisplatin (BOMP)."	1.27	Bleomycin, vincristine, mitomycin-C, and cisplatin in the management of gynecological squamous cell carcinomas. ( Belinson, JL; McClure, M; Richards, AL; Stewart, JA, 1985)
"The most frequent histology was squamous cell carcinoma found in 20 patients."	1.27	[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma]. ( Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R, 1985)
"Mitomycin-C (MMC) is an alkylating agent which has shown significant activity in gynecologic cancers, both in vivo and in vitro."	1.27	Pharmacokinetics of mitomycin-C in plasma and tumor tissue of cervical cancer patients and in selected tissues of female rats. ( Boike, G; Deppe, G; Gove, N; Malviya, VK; Young, JD, 1986)
"Fifty-seven patients with advanced squamous carcinoma of the larynx and hypopharynx were entered on a pilot study of initial therapy using split course radiation therapy combined with simultaneous chemotherapy using mitomycin-C and 5-fluorouracil."	1.27	A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx. ( Beale, FA; Cummings, BJ; Elhakim, T; Harwood, AR; Keane, TJ; Payne, DG; Rawlinson, E, 1986)
" During the first week of radiotherapy, 5-fluorouracil (1000 mg/m2 daily for four days by continuous infusion), and mitomycin (10 mg/m2 on day 1) were administered; four weeks later, a second cycle at the same dosage followed."	1.27	[Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy]. ( Dunst, J; Reichard, U; Sauer, R; Wolf, N, 1987)
" Compared to a group treated in 1970 bis 1982 with the same dosage of irradiation without the combination of chemotherapy the median survival could be raized from nine to 24 months, the two year survival rate improved from 18% to 42%."	1.27	[Simultaneous radio- and chemotherapy of squamous cell carcinoma of the esophagus]. ( Rohloff, R; Tosch, U; Wendt, TG; Willich, N, 1988)
"We report a case of invasive squamous cell carcinoma of the urinary bladder, which was perforated intraperitoneally after intra-arterial chemotherapy."	1.27	[A case of invasive squamous carcinoma of the urinary bladder perforated intraperitoneally after intra-arterial chemotherapy]. ( Sakurai, T; Sugao, H; Takatera, H; Takiuchi, H; Yokokawa, K, 1987)
"For many years surgery has been the treatment of choice for squamous cell carcinoma of the anus, but it is now becoming apparent that well-planned definitive radiation therapy combined with chemotherapy may obviate the need for an abdomino-perineal resection."	1.27	The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum. ( Sischy, B, 1985)
" This three-drug combination appears to be an active regimen in the treatment of non-small-cell bronchogenic carcinoma; however, altered dosage schedules should be examined in order to decrease drug-related toxicity."	1.27	Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer. ( Griffin, JP; Niell, HB, 1985)
"Nine patients with advanced cervical cancer were treated with a combination chemotherapy (MVP) consisting of mitomycin C 8 mg/m2 i."	1.27	[A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1985)

Timeframe	Studies, this research(%)	All Research%
pre-1990	138 (23.00)	18.7374
1990's	135 (22.50)	18.2507
2000's	151 (25.17)	29.6817
2010's	152 (25.33)	24.3611
2020's	24 (4.00)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer[NCT03691441]	Phase 4	280 participants (Anticipated)	Interventional	2018-01-05	Active, not recruiting
Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients[NCT05060471]	Phase 2	27 participants (Anticipated)	Interventional	2021-09-08	Enrolling by invitation
Observational Study on Second Line Treatment of Colorectal Liver Metastases (KRas wt) by Hepatic Intra-arterial Chemoembolization With Dc Beads 70-150 μm Microspheres Preloaded With Irinotecan 200 Mgr Plus Systemic Cetuximab[NCT01891552]		40 participants (Actual)	Observational [Patient Registry]	2013-05-31	Completed
Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy[NCT02369939]	Phase 3	118 participants (Anticipated)	Interventional	2014-12-31	Recruiting
A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal[NCT01858025]	Early Phase 1	25 participants (Actual)	Interventional	2013-07-31	Active, not recruiting
A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250]	Phase 2	264 participants (Actual)	Interventional	2019-11-28	Active, not recruiting
A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT)[NCT03870607]	Phase 2	75 participants (Anticipated)	Interventional	2019-03-13	Recruiting
Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal Canal[NCT05019235]		154 participants (Actual)	Observational	2021-08-05	Active, not recruiting
Tumor Recurrence After Abdominal-perineal Amputation in Squamous Cell Carcinoma of the Anus[NCT05201105]		43 participants (Actual)	Observational	2021-10-15	Completed
A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252]	Phase 3	102 participants (Anticipated)	Interventional	2022-05-07	Recruiting
To Study the Factors Affecting Treatment Responses in Patients With Uterine Cervical Carcinoma Undergoing Neoadjuvant Chemotherapy[NCT05384366]	Phase 3	33 participants (Actual)	Interventional	2020-08-01	Completed
Phase II Trial To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix[NCT04789941]	Phase 2	50 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0[NCT01621217]	Phase 1	21 participants (Anticipated)	Interventional	2012-06-30	Completed
Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial[NCT00454519]	Phase 2	60 participants (Anticipated)	Interventional	2007-03-31	Recruiting
Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study[NCT00068744]	Phase 2/Phase 3	88 participants (Actual)	Interventional	2003-07-31	Terminated (stopped due to low accrual)
Phase II Randomized Trial of Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer[NCT00201747]	Phase 2	80 participants (Actual)	Interventional	2001-09-30	Completed
Observational Study of Functional Outcomes After Chemoradiotherapy for Squamous Cell Cancer of the Anus[NCT01853059]		176 participants (Anticipated)	Observational	2013-10-31	Not yet recruiting
A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487]	Phase 2	46 participants (Anticipated)	Interventional	2023-01-01	Not yet recruiting
Phase III Trial Comparing 2 Chemotherapy Schedules (Preoperative vs Pre and Postoperative) in Stage I and II NSCLC[NCT00198354]	Phase 3	530 participants (Actual)	Interventional	2001-05-31	Completed
Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860]		120 participants (Anticipated)	Interventional	2020-05-26	Recruiting
A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916]	Phase 2	42 participants (Actual)	Interventional	2015-07-31	Completed
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons[NCT02437851]	Phase 2	16 participants (Actual)	Interventional	2015-04-30	Active, not recruiting
Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA)[NCT03100409]		137 participants (Actual)	Interventional	2017-02-01	Terminated (stopped due to The study was closed prematurely because the interim analysis found that subjects in the experimental group had less gastrointestinal toxicity.)
Multicenter Prospective Randomized Study on NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Patients With Cervical Cancer FIGO Stage IB2 and IIB[NCT02422563]	Phase 3	534 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

mitomycin and Carcinoma, Epidermoid

Research Excerpts

Research

Studies (600)

Authors

Clinical Trials (24)

Trial Overview

Reviews

Trials

Other Studies

Article	Year
Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis. Scientific reports, 2022, 08-20, Volume: 12, Issue:1 Topics: Administration, Topical; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Fluorourac	2022
[Anal cancer: Focus on current treatment and future perspective]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2022, Volume: 26, Issue:6-7 Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio	2022
Medical treatment for ocular surface squamous neoplasia. Eye (London, England), 2023, Volume: 37, Issue:5 Topics: Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Neoplasms; Fluorouracil; Humans; Interferon al	2023
Comparison of intravenous 5-Fluorouracil with Oral Capecitabine in the Treatment of Anal Squamous Cell Carcinoma Using Modern Radiation Techniques. The Israel Medical Association journal : IMAJ, 2023, Volume: 25, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Ce	2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp	2023
Randomized Clinical Trials in Localized Anal Cancer. Surgical oncology clinics of North America, 2017, Volume: 26, Issue:4 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino	2017
Systemic Therapies for Advanced Squamous Cell Anal Cancer. Current oncology reports, 2018, 05-04, Volume: 20, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biomarkers, Tumor; Carcinoma, Squamo	2018
Chemoradiotherapy for anal cancer: are we as good as we think? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2019, Volume: 195, Issue:5 Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Combined Modality Thera	2019
Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. International journal of radiation oncology, biology, physics, 2019, 11-01, Volume: 105, Issue:3 Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma,	2019
[Brachytherapy for anal cancers]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2013, Volume: 17, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous C	2013
Anal cancer treatment: current status and future perspectives. World journal of gastroenterology, 2015, Feb-28, Volume: 21, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; C	2015
Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature. BMJ case reports, 2016, May-10, Volume: 2016 Topics: Administration, Topical; Carcinoma, Squamous Cell; Child; Cytoreduction Surgical Procedures; Eye Neo	2016
[Rectal squamous cell carcinoma treatment: Retrospective experience in two French university hospitals, review and proposals]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2016, Volume: 20, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin	2016
Evolution and Management of Treatment-Related Toxicity in Anal Cancer. Surgical oncology clinics of North America, 2017, Volume: 26, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradio	2017
Hemolytic uremic syndrome. Oncology nursing forum, 2008, Volume: 35, Issue:4 Topics: Adult; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antihypertensive Agents; Anus Neoplasm	2008
[Topical Mitomycin C as a therapy of conjunctival tumours]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2008, Volume: 105, Issue:8 Topics: Administration, Topical; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; C	2008
Management of anal cancer in 2010. Part 2: current treatment standards and future directions. Oncology (Williston Park, N.Y.), 2010, Apr-30, Volume: 24, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin;	2010
Anal cancer: an examination of radiotherapy strategies. International journal of radiation oncology, biology, physics, 2011, Apr-01, Volume: 79, Issue:5 Topics: Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic	2011
Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. Current oncology reports, 2011, Volume: 13, Issue:3 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anus Neoplasms; Bevacizum	2011
[Management of anal canal carcinoma]. Revue medicale suisse, 2011, May-25, Volume: 7, Issue:296 Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell	2011
[A case of perianal squamous cell carcinoma attaining a complete response over five years with chemoradiotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anus Neoplasms; Biopsy; Carcinoma, Squ	2011
Topical therapies for periorbital cutaneous malignancies: indications and treatment regimens. Current opinion in ophthalmology, 2012, Volume: 23, Issue:5 Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, S	2012
[Neoadjuvant intraarterial chemotherapy with nedaplatin, peplomycin and mitomycin C for advanced cervical cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra	2003
Palliative cytostatic treatment of cervical carcinoma. European journal of gynaecological oncology, 2003, Volume: 24, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Carcinoma, Squamous Cell; C	2003
Squamous cell carcinoma of the anal margin. Journal of surgical oncology, 2004, May-01, Volume: 86, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel	2004
Chemotherapeutic options in the management of anal cancer. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:12 Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; HIV Se	2004
[Decision making in non resectable head and neck tumours]. Laryngo- rhino- otologie, 2005, Volume: 84, Issue:3 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic	2005
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC cancer, 2006, Jan-31, Volume: 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co	2006
Current treatment for localized anal carcinoma. Current opinion in oncology, 2007, Volume: 19, Issue:4 Topics: Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Humans; Mi	2007
Chemo-radiotherapy: an alternative to surgery for squamous cell carcinoma of the rectum--report of six patients and literature review. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2009, Volume: 11, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co	2009
Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer treatment reviews, 1983, Volume: 10, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sm	1983
The biology and treatment of superficial bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Squamous Cell; Carcinoma, Trans	1984
Synchronous chemotherapy and radiotherapy for carcinoma of the anal canal--an alternative to abdominoperineal resection. The Australian and New Zealand journal of surgery, 1984, Volume: 54, Issue:2 Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous C	1984
Squamous cell carcinoma complicating idiopathic inflammatory bowel disease. Journal of surgical oncology, 1995, Volume: 59, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transiti	1995
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study. International journal of radiation oncology, biology, physics, 1994, Jan-01, Volume: 28, Issue:1 Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell;	1994
Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. International journal of radiation oncology, biology, physics, 1993, Aug-01, Volume: 26, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cisplatin; Combined Modali	1993
[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial]. Bulletin du cancer, 1995, Volume: 82, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co	1995
Anal canal cancer: current treatment and results. Annals of the Academy of Medicine, Singapore, 1996, Volume: 25, Issue:3 Topics: Anal Canal; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant	1996
Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer, 1999, Apr-15, Volume: 85, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus	1999
Chemotherapy of advanced or recurrent cervical carcinoma with a consecutive low-dose cisplatin combined with bleomycin, vincristine, and mitomycin-C (consecutive low-dose BOMP). Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo	2000
Preliminary results of chemoradiation as a primary treatment for vulvar carcinoma. International journal of radiation oncology, biology, physics, 2000, Sep-01, Volume: 48, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C	2000
Chemoradiation for carcinoma of the cervix: advances and opportunities. Radiation research, 2000, Volume: 154, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A	2000
[Radiochemotherapy in anal canal epidermoid cancer]. Annales de chirurgie, 2000, Volume: 125, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin;	2000
A solitary bronchial papilloma with malignant changes. Internal medicine (Tokyo, Japan), 2001, Volume: 40, Issue:1 Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy,	2001
[A case of secondary myelodysplastic syndrome following chemotherapy for lung cancer]. Nihon Kyobu Shikkan Gakkai zasshi, 1992, Volume: 30, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio	1992
Update in cancer chemotherapy, Part III: Lung cancer, Part 1. Journal of the National Medical Association, 1985, Volume: 77, Issue:10 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Carcinoma; C	1985

Authors	Studies
Guerra, GR	1
Kong, JC	1
Millen, RM	1
Read, M	1
Liu, DS	1
Roth, S	1
Sampurno, S	1
Sia, J	1
Bernardi, MP	1
Chittleborough, TJ	1
Behrenbruch, CC	1
Teh, J	1
Xu, H	1
Haynes, NM	1
Yu, J	1
Lupat, R	1
Hawkes, D	1
Di Costanzo, N	1
Tothill, RW	1
Mitchell, C	1
Ngan, SY	4
Heriot, AG	1
Ramsay, RG	1
Phillips, WA	1
Martin, D	3
Schreckenbach, T	1
Ziegler, P	1
Filmann, N	1
Kalinauskaite, G	1
Tinhofer, I	1
Budach, V	6
Gani, C	1
Zips, D	1
Schimek-Jasch, T	1
Schäfer, H	1
Grosu, AL	1
Thomas, E	1
Krause, M	1
Dapper, H	1
Combs, S	1